Damon DeSantis - 20 Jun 2022 Form 4 Insider Report for INTEGRATED BIOPHARMA INC (INBP)

Reporting relationship: Director
Issuer ticker: INBP
Reported as of: 20 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jun 2022, 17:33:52 UTC
Prior SEC filing: 22 Feb 2023
Next SEC filing: 05 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Damon DeSantis

Key filing fact

Damon DeSantis filed Form 4 for INTEGRATED BIOPHARMA INC (INBP) on 21 Jun 2022.

Key facts

This page summarizes Damon DeSantis's Form 4 filing for INTEGRATED BIOPHARMA INC (INBP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Jun 2022, 17:33.

Change

Previous filing in this sequence was filed on 22 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INBP transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +50,000
Change %
Price: $0.000000
Shares after: 50,000
Date: 20 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The exercise price of each stock option will be the closing price of the Issuer's Common Stock on June 27, 2022, which represents the fifth trading day after the grant date.

Footnote F2

The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2022, December 31, 2022, March 31, 2023 and June 30, 2023.